SEC Form 10-K filed by Biodesix Inc.

William Blair upgraded Biodesix from Mkt Perform to Outperform

William Blair downgraded Biodesix from Outperform to Mkt Perform

Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

4 - BIODESIX INC (0001439725) (Issuer)

4 - BIODESIX INC (0001439725) (Issuer)

4 - BIODESIX INC (0001439725) (Issuer)

4 - BIODESIX INC (0001439725) (Issuer)

4 - BIODESIX INC (0001439725) (Issuer)

4 - BIODESIX INC (0001439725) (Issuer)

LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences: Craig-Hallum 23rd Annual Institutional Investor Conference1x1 meetings only Date: Thursday, May 28, 2026Location: Minneapolis, MN William Blair 46th Annual Growth Stock ConferencePresentation and 1x1 meetings Presentation Date and Time: Wednesday, June 3, 2026 at 2:00 PM CTLocation: Chicago, IL TD Cowen Annual Tools/Dx Revolution 1x1 meetings onlyDate: Wednesday, June 24, 2026Location: Dana Point, CA The presentation will be webcast live and availab

LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung® testing will be shared at the American Thoracic Society (ATS) Annual Meeting, May 15 – 20, 2026 | Orlando, FL. The presentations further reinforce the accelerating adoption of Biodesix blood-based testing for earlier detection of lung cancer. "The presentations at ATS highlight the real-world clinical value and economic advantages of lung nodule management programs that use Nodify Lung® testing for risk stratification," said Scott Hutton, CEO of Biodesix. "It is encouraging t

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2026. "Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business," said Scott Hutton, Chief Executive Officer. "Test volumes gre

EFFECT - BIODESIX INC (0001439725) (Filer)

S-3 - BIODESIX INC (0001439725) (Filer)

8-K - BIODESIX INC (0001439725) (Filer)

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2026. "Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business," said Scott Hutton, Chief Executive Officer. "Test volumes gre

LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should access the live call by dialing (800) 715-9871 (domestic) or +1 (646) 307-1963 (international) and enter the passcode 2430172.

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

SC 13G/A - BIODESIX INC (0001439725) (Subject)

SC 13G - BIODESIX INC (0001439725) (Subject)

SC 13D/A - BIODESIX INC (0001439725) (Subject)